MUNICH, GERMANY--(Marketwire - November 05, 2012) - MorphoSys AG /
MorphoSys Announces Presentation of Preclinical Data on MOR202 and MOR208
2012 American Society of Hematology Annual Meeting. Processed and
transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today the
publication of additional preclinical data on its two proprietary cancer
programs MOR208 and MOR202 in the online issue of the peer-reviewed medical
journal BLOOD. The data sets further underline the potential of both
to result in new treatment options for various forms of blood-borne cancer.
data will be presented at the 2012 American Society of Hematology (ASH)
meeting on December 8-11, 2012 in Atlanta.
MOR208, an anti-CD19 antibody with a proprietary modification to the Fc
has successfully concluded a phase 1/2a clinical trial in chronic
leukemia (CLL). The program is on track to enter clinical development in
non-Hodgkin's lymphoma (NHL) and acute lymphoblastic leukemia (ALL). The
in vitro study to be presented at ASH examined MOR208's potential to
antibody-dependent cell-mediated cytotoxicity (ADCC) relative to a native
non-engineered anti-CD19 antibody. In the study, MOR208 showed
enhanced cytotoxicity triggering killing of cancer cells derived from both
pediatric and adult patients with ALL. MOR208 was twice as effective as the
non-engineered antibody and required lower antibody levels and lower
MOR202, an anti-CD38 HuCAL antibody, is currently being tested in a phase
study in patients with relapsed or refractory multiple myeloma (MM). Having
previously identified ADCC as an effector mechanism of MOR202, the
data to be presented at ASH demonstrate the antibody's capability to induce
killing of MM patient cells via antibody dependent cellular phagocytosis
as an additional potent mechanism.
"These findings for our proprietary cancer programs MOR202 and MOR208 are
encouraging and highlight the significant potential of both candidates.
may represent a promising approach for treatment of pediatric and adult
commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG.
MOR202, the additional effector mechanism bodes well for future clinical
development in multiple myeloma."
In total, MorphoSys currently has four proprietary clinical programs
namely MOR208 and MOR202, as well as MOR103, a fully human HuCAL antibody
directed against GM-CSF (granulocyte macrophage-colony stimulating factor),
is being developed in rheumatoid arthritis and multiple sclerosis.
The full abstracts are available on
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
Together with its pharmaceutical partners, MorphoSys has built a
pipeline of more than 70 human antibody drug candidates for the treatment
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow.
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,
RapMAT®, arYla®, Ylanthia®
and 100 billion high potentials® are registered trademarks of
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a
of MorphoSys AG.
This communication contains certain forward-looking statements concerning
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements
far as the wording of the relevant press release is concerned.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE